Wegovy and Ozempic: key differences patients should understand
People researching medical weight management often come across two medicines that appear very similar: Wegovy and Ozempic. Both are produced by Novo Nordisk and both contain the same active ingredient, semaglutide.
Because they share the same medicine, many patients assume they are interchangeable. In practice, they are licensed for different purposes and used in slightly different ways in clinical settings. Understanding these differences can help patients have more informed discussions during a consultation.
Understanding semaglutide
Semaglutide belongs to a class of medicines known as GLP 1 receptor agonists. These medicines mimic a hormone involved in appetite regulation and digestion.
They can influence several processes in the body, including:
• slowing stomach emptying
• increasing feelings of fullness
• reducing appetite signals
• supporting blood glucose regulation
Because of these effects, semaglutide has been studied both for diabetes management and for weight management.
Licensing and purpose
The main difference between the two medicines relates to how they are licensed.
Wegovy
Wegovy is specifically licensed for weight management in adults with obesity or in people who are overweight with certain weight related health conditions.
Ozempic
Ozempic is licensed for the treatment of type 2 diabetes. It is primarily prescribed to help control blood glucose levels and reduce certain cardiovascular risks associated with diabetes.
Although both medicines contain semaglutide, their approved uses are different.
Differences in dosing
Another key difference is the dosing range used for each medicine.
Wegovy is prescribed at higher doses that are designed for weight management. Treatment usually begins at a low dose and gradually increases over several weeks. This gradual increase is intended to help reduce the likelihood of side effects while the body adjusts.
Ozempic is generally prescribed at lower doses that are appropriate for managing blood glucose levels in people with type 2 diabetes.
The difference in dosing is one reason the medicines are used in different clinical contexts.
Expected weight changes
Clinical research has shown that semaglutide can support weight reduction when combined with lifestyle changes. In weight management studies using the dosing schedule associated with Wegovy, participants experienced significant average weight reduction over time.
When semaglutide is used at the lower doses associated with diabetes treatment, weight reduction may still occur but it is not the primary purpose of the medication.
Availability in the UK
Both medicines are available in the UK through regulated prescribing pathways. Because they are prescription medicines, they cannot be supplied without a clinician assessing whether they are suitable for the individual patient.
At Keltoi, treatment options are discussed during a clinician led consultation. The clinician reviews medical history, current health factors, and treatment goals before considering whether any medication may be appropriate.
If a prescription is issued, the medication is supplied through a licensed pharmacy.
Safety and side effects
Because both medicines contain semaglutide, they share a similar side effect profile. Some people experience symptoms such as nausea, digestive discomfort, or changes in appetite, particularly during the early stages of treatment.
Clinicians typically introduce treatment gradually to help minimise these effects. Patients are also advised about symptoms that should be discussed with a healthcare professional.
Careful medical assessment before starting treatment helps ensure that medicines are prescribed responsibly.
Discussing options with a clinician
Choosing a treatment approach for weight management often involves considering a range of factors, including health history, existing conditions, and personal goals.
A consultation provides an opportunity to discuss how different treatments work, what outcomes may be realistic, and whether a particular option may be suitable.
Information provided for general guidance only. Individual suitability is assessed by a clinician.